Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases.